Role of paraoxonase 1 (PON1) in organophosphate metabolism: Implications in neurodegenerative diseases

Toxicology and Applied Pharmacology

Volumn 256, Issue 3, 2011, Pages 418-424

  Androutsopoulos, Vasilis P ^a   Kanavouras, Konstantinos ^a   Tsatsakis, Aristidis M ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

Alzheimer's; Organophosphate pesticides; Paraoxonase 1; Parkinson's; Polymorphism

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; CHLORPYRIFOS; CHLORPYRIFOS OXON; DIAZOXON; FREE RADICAL; LIPOPROTEIN; ORGANOPHOSPHATE PESTICIDE; PARAOXON; UNCLASSIFIED DRUG;

ALLELE; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; DEGENERATIVE DISEASE; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; EPIDEMIOLOGICAL DATA; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; HYDROLYSIS; NERVE CELL LESION; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PHOSPHATE METABOLISM; PROTEIN FUNCTION; REVIEW;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ARYLDIALKYLPHOSPHATASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEURODEGENERATIVE DISEASES; ORGANOPHOSPHORUS COMPOUNDS; PARKINSON DISEASE, SECONDARY;

ANIMALIA;

EID: 80855132813     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.08.009     Document Type: Review

References (65)

1. Akhmedova S., Anisimov S., Yakimovsky A., Schwartz E. Gln→Arg 191 polymorphism of paraoxonase and Parkinson's disease. Hum. Hered. 1999, 49:178-180.
2. Akhmedova S.N., Yakimovsky A.K., Schwartz E.I. Paraoxonase 1 Met-Leu 54 polymorphism is associated with Parkinson's disease. J. Neurol. Sci. 2001, 184:179-182.
3. BenMoyal-Segal L., Soreq H. Gene-environment interactions in sporadic Parkinson's disease. J. Neurochem. 2006, 97:1740-1755.
4. BenMoyal-Segal L., Vander T., Shifman S., Bryk B., Ebstein R., Marcus E.L., Stressman J., Darvasi A., Herishanu Y., Friedman A., Soreq H. Acetylcholinesterase/paraoxonase interactions increase the risk of insecticide-induced Parkinson's disease. FASEB J. 2005, 19:452-454.
5. Bertram L., McQueen M.B., Mullin K., Blacker D., Tanzi R.E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 2007, 39:17-23.
6. Carmine A., Buervenich S., Sydow O., Anvret M., Olson L. Further evidence for an association of the paraoxonase 1 (PON1) Met-54 allele with Parkinson's disease. Mov. Disord. 2002, 17:764-766.
7. Cellini E., Tedde A., Bagnoli S., Nacmias B., Piacentini S., Bessi V., Bracco L., Sorbi S. Association analysis of the paraoxonase-1 gene with Alzheimer's disease. Neurosci. Lett. 2006, 408:199-202.
8. Chambers J.E. PON1 multitasks to protect health. Proc. Natl. Acad. Sci. 2008, 105:12639-12640.
9. Chiò A., Schymick J.C., Restagno G., Scholz S.W., Lombardo F., Lai S.L., et al. A two-stage genome-wide association study of sporadic amyotrophic lateral sclerosis. Hum. Mol. Genet. 2009, 18:1524-1532.
10. Clarimon J., Eerola J., Hellstrom O., Tienari P.J., Singleton A. Paraoxonase 1 (PON1) gene polymorphisms and Parkinson's disease in a Finish population. Neurosci. Lett. 2004, 367:168-170.
11. Costa L.G., Mc Donald B.E., Murphy S.D., Omenn G.S., Richter R.J., Motulsky A.G., Furlong C.E. Serum paraoxonase and its influence on paraoxon and chlorpyrifos oxon toxicity in rats. Toxicol. Appl. Pharmacol. 1990, 76:66-76.
12. Costa L.G., Cole T.B., Jarvik G.P., Furlong C.E. Functional genomics of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease and drug metabolism. Annu. Rev. Med. 2003, 54:371-392.
13. Costa L.G., Cole T.B., Vitalone A., Furlong C.E. Measurement of paraoxonase status as a potential biomarker of susceptibility to organophosphate toxicity. Clin. Chim. Acta 2005, 352:37-47.
14. Costa L.G., Vitalone A., Cole T.B., Furlong C.E. Modulation of paraoxonase (PON1) activity. Biochem. Pharmacol. 2005, 69:541-550.
15. Cronin S., Greenway M.J., Prehn J.H., Hardiman O. Paraoxonase promoter and intronic variants modify risk of sporadic amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 2007, 78:984-986.
16. Dantoine T.F., Drouet M., Debord J., Merle L., Cogne M., Charmes J.P. Paraoxonase 1 192/55 gene polymorphisms in Alzheimer's disease. Ann. N. Y. Acad. Sci. 2002, 977:239-244.
17. Diekstra F.P., Beleza-Meireles A., Leigh N.P., Shaw C.E., Al-Chalabi A. Interaction between PON1 and population density in amyotrophic lateral sclerosis. Neuroreport 2009, 20:186-190.
18. Draganov D.I., Teiber J.F., Speelman A., Osawa Y., Sunahara R., La Du B.N. Human paraoxonases (PON1, PON2 and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid Res. 2005, 46:1239-1247.
19. Eaton D.L. Biotransformation enzyme polymorphism and pesticide susceptibility. Neurotoxicology 2000, 21:101-111.
20. Erlich P.M., Lunetta K.L., Cupples L.A., Huyck M., Green R.C., Baldwin C.T., Farrer L.A. Polymorphisms in the PON gene cluster are associated with Alzheimer disease. Hum. Mol. Genet. 2006, 15:77-85.
21. Erlich, P.M., Lunetta, K.L., Cupples, L.A., Abraham, C.R., Green, R.C., Baldwin, C.T., Farrer, L.A., Serum paraoxonase activity is associated with variants in the PON gene cluster and risk of Alzheimer disease. Neurobiol. Aging.
22. Firestone J.A., Smith-Weller T., Franklin G., Swanson P., Longstreth W.T., Checkoway H. Pesticides and risk of Parkinson disease: a population-based case-control study. Arch. Neurol. 2005, 62:91-95.
23. Fong C.S., Cheng C.W., Wu R.M. Pesticides exposure and genetic polymorphism of paraoxonase in the susceptibility of Parkinson's disease. Acta Neurol. Taiwan 2005, 14:55-60.
24. Furlong C.E. Genetic variability in the cytochrome P450-paraoxonase 1 (PON1) pathway for detoxication of organophosphorous compounds. J. Biochem. Mol. Toxicol. 2007, 21:197-205.
25. Furlong C.E., Cole T.B., Jarvik G.P., Pettan-Brewer C., Geiss G.K., Richter R.J., Shih D.M., Tward A.D., Lusis A.J., Costa L.G. Role of paraoxonase (PON1) status in pesticide sensitivity: genetic and temporal determinants. Neurotoxicology 2005, 26:651-659.
26. Gupta N., Gill K., Singh S. Paraoxonases: structure, gene polymorphism & role in coronary artery disease. Indian J. Med. Res. 2009, 130:361-368.
27. He X.M., Zhang Z.X., Zhang J.W., Zhou Y.T., Tang M.N., Wu C.B., Hong Z. Gln192Arg polymorphism in paraoxonase 1 gene is associated with Alzheimer's disease in a Chinese Han ethnic population. Chin. Med. J. 2006, 119:1204-1209.
28. Herishanu Y.O., Medvedovski M., Goldsmith J.R., Kordysh E. A case-control study of Parkinson's disease in urban populations of southern Israel. Can. J. Neurol. Sci. 2001, 28:144-147.
29. Ikeda K., Nakamura Y., Kiyozuka T., Ayoagi J., Hirayama T., Nagata R., Ito H., Iwamoto K., Murata K., Yoshii Y., Kawabe K., Iwasaki Y. Serological profiles of urate, paraoxonase-1, ferritin and lipid in Parkinson's disease: changes linked to disease progression. Neurodegener. Dis. 2011, 8:252-258.
30. Kamel F., Hoppin J.A. Association of pesticide exposure with neurologic dysfunction and disease. Environ. Health Perspect. 2004, 112:950-958.
31. Kanavouras, K., Tzatzarakis, M.N., Mastorodemos, V., Plaitakis, A., Plaitakis, A., Tsatsakis, A.M., in press. A case report of motor neuron disease in a patient showing significant level of DDTs, HCHs and organophosphate metabolites in hair as well levels of hexane and toluene in blood. Toxicol. Appl.
32. Kasperaviciute D., Weale M.E., Shianna K.V., Banks G.T., Simpson C.L., Hansen V.K., et al. Large-scale pathways-based association study in amyotrophic lateral sclerosis. Brain 2007, 2007(130):2292-2301.
33. Kaufer D., Friedman A., Seidman S., Soreq H. Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature 1998, 393:373-377.
34. Kelada S.N., Costa-Mallen P., Checkoway H., Viernes H.A., Farin F.M., Smith-Weller T., Franklin G.M., Costa L.G., Longstreth W.T., Furlong C.E., Jarvik G.P., Swanson P.D. Paraoxonase 1 promoter and coding region polymorphisms in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2003, 74:546-547.
35. Landers J.E., Shi L., Cho T.J., Glass J.D., Shaw C.E., Leigh P.N., Diekstra F., Polak M., Rodriguez-Leyva I., Niemann S., Traynor B.J., McKenna-Yasek D., Sapp P.C., Al-Chalabi A., Wills A.M., Brown R.H. A common haplotype within the PON1 promoter region is associated with sporadic ALS. Amyotroph. Lateral Scler. 2008, 9:306-314.
36. Lang A.E., Lozano A.M. Parkinson's disease. First of two parts. N. Engl. J. Med. 1998, 339:1130-1143.
37. Le Couteur D.G., McLean A.J., Taylor M.C., Woodham B.L., Board P.G. Pesticides and Parkinson's disease. Biomed. Pharmacother. 1999, 53:122-130.
38. Leduc V., Poirier J. Polymorphisms at the paraoxonase 1 L55M and Q192R loci affect the pathophysiology of Alzheimer's disease: emphasis on the cholinergic system and beta-amyloid levels. Neurodegener. Dis. 2008, 5:225-227.
39. Leduc V., Theroux L., Dea D., Robitaille Y., Poirier J. Involvement of paraoxonase 1 genetic variants in Alzheimer's disease neuropathology. Eur. J. Neurosci. 2009, 30:1823-1830.
40. Li H.L., Liu D.P., Liang C.C. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J. Mol. Med. 2003, 81:766-779.
41. Li W.F., Furlong C.E., Costa L.G. Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol. Lett. 1995, 76:219-226.
42. Li W.F., Costa L.G., Richter R.J., Hagen T., Shih D.M., Tward A., Lusis A.J., Furlong C.E. Catalytic efficiency determines the in vivo efficacy of PON1 for detoxifying organophosphates. Pharmacogenetics 2000, 10:767-779.
43. Mackness B., Mackness M.I., Arrol S., Turkie W., Durrington P.N. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br. J. Pharmacol. 1997, 122:265-268.
44. Manthripragada A.D., Costello S., Cockburn M.G., Bronstein J.M., Ritz B. Paraoxonase 1, agricultural organophosphate exposure, and Parkinson disease. Epidemiology 2010, 21:87-94.
45. Morahan J.M., Yu B., Trent R.J., Pamphlett R. A gene-environment study of the paraoxonase 1 gene and pesticides in amyotrophic lateral sclerosis. Neurotoxicology 2007, 28(3):532-540.
46. Oliveira S.A., Mansur A.P., Ribeiro C.C., Ramires J.A., Annichino-Bizzacchi J.M. PON1M/L55M mutation protects high-risk patients against coronary artery disease. Int. J. Cardiol. 2004, 94:73-77.
47. Pola R., Gaetani E., Flex A., Gerardino L., Aloi F., Flore R., Serricchio M., Pola P., Bernabei R. Lack of association between Alzheimer's disease and Gln-Arg 192 Q/R polymorphism of the PON-1 gene in an Italian population. Dement. Geriatr. Cogn. Disord. 2003, 15:88-91.
48. Pola R., Flex A., Ciaburri M., Rovella E., Valiani A., Reali G., Silveri M.C., Bernabei R. Responsiveness to cholinesterase inhibitors in Alzheimer's disease: a possible role for the 192 Q/R polymorphism of the PON-1 gene. Neurosci. Lett. 2005, 382:338-341.
49. Saeed M., Siddique N., Hung W.Y., Usacheva E., Liu E., Sufit R.L., Heller S.L., Haines J.L., Pericak-Vance M., Siddique T. Paraoxonase cluster polymorphisms are associated with sporadic ALS. Neurology 2006, 67:771-776.
50. Shih D.M., Gu L., Xia Y.R., Navab M., Li W.F., Hama S., Castellani L.W., Furlong C.E., Costa L.G., Fogelman A.M., Luisis A.J. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998, 394:284-287.
51. Slowik A., Tomik B., Wolkow P.P., Partyka D., Turaj W., Malecki M.T., Pera J., Dziedzic T., Szczudlik A., Figlewicz D.A. Paraoxonase gene polymorphisms and sporadic ALS. Neurology 2006, 67(5):766-770.
52. Sutedja N.A., Veldink J.H., Fischer K., Kromhout H., Heederik D., Huisman M.H., Wokke J.H., van den Berg L.H. Exposure to chemicals and metals and risk of amyotrophic lateral sclerosis: a systematic review. Amyotroph. Lateral Scler. 2009, 10(5-6):302-309.
53. Ticozzi N., LeClerc A.L., Keagle P.J., Glass J.D., Wills A.M., van Blitterswijk M., Bosco D.A., Rodriguez-Leyva I., Gellera C., Ratti A., Taroni F., McKenna-Yasek D., Sapp P.C., Silani V., Furlong C.E., Brown R.H., Landers J.E. Ann. Neurol. 2010, 68:102-107.
54. Tsatsakis A.M., Aguridakis P., Michalodimitrakis M.N., Tsakalov A.K., Alegakis A.K., Koumantakis E., Troulakis G. Experiences with acute organophosphate poisonings in Crete. Vet. Hum. Toxicol. 1996, 38:101-107.
55. Tsatsakis A.M., Zafiropoulos A., Tzatzarakis M.N., Tzanakakis G.N., Kafatos A. Relation of PON1 and CYP1A1 genetic polymorphisms to clinical findings in a cross sectional study of a Greek rural population professionally exposed to pesticides. Toxicol. Lett. 2009, 186:66-72.
56. Tsatsakis A.M., Androutsopoulos V.P., Zafiropoulos A., Babatsikou F., Alegakis A., Dialyna I., Tzatzarakis M., Koutis C. Associations of xenobiotic-metabolizing enzyme-genotypes PON1Q192R, PON1L55M AND CYP1A1*2A MspI with pathological symptoms of a rural population in south Greece. Xenobiotica 2011, 41(10):914-925.
57. Unur M., Demirez E., Agachan B., Gormus U., Ergen A., Dalan B., Isbir T. The relationship of oral disturbances of diabetes mellitus patients with paraoxonase gene polymorphisms. Cell Biochem. Funct. 2008, 26:870-873.
58. Valdmanis P.N., Kabashi E., Dyck A., Hince P., Lee J., Dion P., D'Amour M., Souchon F., Bouchard J.P., Salachas F., Meininger V., Andersen P.M., Camu W., Dupré N., Rouleau G.A. Association of paraoxonase gene cluster. Polymorphisms with ALS in France, Quebec, and Sweden. Neurology 2008, 71:514-520.
59. van Es M.A., Veldink J.H., Saris C.G., Blauw H.M., van Vught P.W., Birve A., et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat. Genet. 2009, 41:1083-1087.
60. Wills A.M., Landers J.E., Zhang H., Richter R.J., Caraganis A.J., Cudkowicz M.E., Furlong C.E., Brown R.H. Paraoxonase 1 (PON1) organophosphate hydrolysis is not reduced in ALS. Neurology 2008, 70:929-934.
61. Wills A.M., Cronin S., Slowik A., Kasperaviciute D., Van Es M.A., Morahan J.M., Valdmanis P.N., et al. A large-scale international meta-analysis of paraoxonase gene polymorphisms in sporadic ALS. Neurology 2009, 73:16-24.
62. Wingo, T.S., Rosen, A., Cutler, D.J., Lah, J.J., Levey, A.I., in press. Paraoxonase-1 polymorphisms in Alzheimer's disease, Parkinson's disease, and AD-PD spectrum diseases. Neurobiol. Ag.
63. Zafiropoulos A., Linardakis M., Jansen E.H., Tsatsakis A.M., Kafatos A., Tsanakakis G.N. Paraoxonase 1 R/Q alleles are associated with differential accumulation of saturated versus 20:5n3 fatty acid in human adipose tissue. J. Lipid Res. 2010, 51:1991-2000.
64. Zawiślak D., Ostrowska M., Golenia A., Marona M., Tomik B., Wołkow P., Gryz-Kurek E., Szczudlik A., Słowik A. The -A162G polymorphism of the PON1 gene and the risk of sporadic amyotrophic lateral sclerosis. Neurol. Neurochir. Pol. 2010, 44:246-250.
65. Zintzaras E., Hadjigeorgiou G.M. Association of paraoxonase 1 gene polymorphisms with risk of Parkinson's disease: a meta-analysis. J. Hum. Genet. 2004, 49:474-481.